Polypid
Open
$4.49
Prev. Close
$4.49
High
$4.49
Low
$4.49
Market Snapshot
$70.91M
-2.3
1.04
72
PolyPid Ltd. operates as a phase 3 biopharma company. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
PolyPid outperforms NLS Pharmaceutics in analyst ratings and growth potential, highlighting its strong position in the biopharmaceutical industry focused on innovative therapies.
PolyPid Ltd. operates as a phase 3 biopharma company. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.